The purpose of this study is to compare overall survival for patients receiving ipilimumab plus bevacizumab versus ipilimumab alone
John McCann, MD
John McCann, MD
Cancer,
Cancer - Brain,
Cancer - Breast,
Cancer - Colon,
Cancer - Esophogus,
Cancer-Gynecologic,
Cancer - Kidney,
Cancer - Leukemia,
Cancer - Lung,
Cancer - Lymphoma,
Cancer - Melanoma,
Cancer - Multiple Myeloma,
Cancer - Pancreatic,
Cancer - Prostate
D'Amour Center For Cancer Care
3350 Main Street
Springfield, MA 01199
John McCann, MD
Cancer,
Cancer - Brain,
Cancer - Breast,
Cancer - Colon,
Cancer - Esophogus,
Cancer-Gynecologic,
Cancer - Kidney,
Cancer - Leukemia,
Cancer - Lung,
Cancer - Lymphoma,
Cancer - Melanoma,
Cancer - Multiple Myeloma,
Cancer - Pancreatic,
Cancer - Prostate
D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
The purpose of this study is to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment of either interferon alfa-2b or ipilimumab. In this study, you will get either MK-3475 or a choice of either interferon alfa-2b or ipilimumab.
John McCann, MD
Cancer - Melanoma
D'amour Center for Cancer Care
3350 Main Street
Springfield MA 01199
The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together. We would also like to find out what effects, good and bad, that this combination of drugs may have on your cancer.
John McCann, MD
Cancer - Melanoma,
Cancer
D'amour Center for Cancer Care
3350 Main Street
Springfield MA 01199
Page 1 of 1 | Results 1 - 5 of 5